This six-page guideline summary is a 2006 update of the American Society of Clinical Oncology's (ASCO) recommendations for the use of white blood cell growth factors.
This guideline summary addresses the following topics:
Four tables provide a summary the 2006 recommendations; a clinical prediction model for identifying patients at higher risk of complications; recommendations for CSF initiation, duration, dosing, and administration; and the incidence of hematologic and infectious toxicities associated with selected chemotherapy regimens. A summary of discussion and methodology, as well as information about additional resources, are also presented.
American Society of Clinical Oncology
Guideline-Related; Patient/Medication Safety
Last updated: July 28, 2009.
AHRQ Home | Questions? | Contact AHRQ | Site Map | Accessibility | Privacy Policy | Freedom of Information Act | Disclaimers U.S. Department of Health & Human Services | The White House | USA.gov: The U.S. Government's Official Web Portal
Agency for Healthcare Research and Quality 540 Gaither Road Rockville, MD 20850 Telephone: (301) 427-1364